Adaptive Biotechnologies Corp logo

ADPT

Adaptive Biotechnologies Corp

$11.12

Earnings Summary

Revenue
$43.66Mn
Net Profits
$-52.05Mn
Net Profit Margins
-119.21%

Highlights

Revenue:

Adaptive Biotechnologies Corp’s revenue jumped 13.39% since last year same period to $43.66Mn in the Q2 2022. On a quarterly growth basis, Adaptive Biotechnologies Corp has generated 13.05% jump in its revenue since last 3-months.

Net Profits:

Adaptive Biotechnologies Corp’s net profit fell -5.57% since last year same period to $-52.05Mn in the Q2 2022. On a quarterly growth basis, Adaptive Biotechnologies Corp has generated 17.12% jump in its net profits since last 3-months.

Net Profit Margins:

Adaptive Biotechnologies Corp’s net profit margin jumped 6.9% since last year same period to -119.21% in the Q2 2022. On a quarterly growth basis, Adaptive Biotechnologies Corp has generated 26.69% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Adaptive Biotechnologies Corp post its latest quarter earnings

EPS Estimate Current Quarter
-0.43
EPS Estimate Current Year
-0.43

Highlights

EPS Estimate Current Quarter:

Adaptive Biotechnologies Corp’s earning per share (EPS) estimates for the current quarter stand at -0.43 - a 6.52% jump from last quarter’s estimates.

EPS Estimate Current Year:

Adaptive Biotechnologies Corp’s earning per share (EPS) estimates for the current year stand at -0.43.

Key Ratios

Key ratios of the Adaptive Biotechnologies Corp post its Q2 2022 earnings

Earning Per Share (EPS)
-0.37
Return on Assets (ROA)
-0.16
Return on Equity (ROE)
-0.38
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Adaptive Biotechnologies Corp’s earning per share (EPS) fell -5.71% since last year same period to -0.37 in the Q2 2022. This indicates that the Adaptive Biotechnologies Corp has generated -5.71% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Adaptive Biotechnologies Corp’s return on assets (ROA) stands at -0.16.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Adaptive Biotechnologies Corp’s return on equity (ROE) stands at -0.38.

Dividend Per Share (DPS):

Adaptive Biotechnologies Corp declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-04
-0.46
-0.44
4.35%
2022-08-03
-0.43
-0.37
13.95%

Company Information

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Its proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

Organisation
Adaptive Biotechnologies Corp
Headquarters
Seattle, Washington, US
Employees
622
Industry
Commercial Services
CEO
Chad Robins